X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (935) 935
proprotein convertase 9 - antagonists & inhibitors (488) 488
animals (381) 381
cholesterol, ldl - blood (360) 360
proprotein convertases - antagonists & inhibitors (303) 303
anticholesteremic agents - therapeutic use (293) 293
male (286) 286
proprotein convertase 9 (269) 269
hypercholesterolemia - drug therapy (252) 252
antibodies, monoclonal - therapeutic use (250) 250
cholesterol (249) 249
female (244) 244
cardiac & cardiovascular systems (209) 209
hypercholesterolemia (204) 204
treatment outcome (198) 198
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (193) 193
statins (190) 190
middle aged (179) 179
pcsk9 (179) 179
monoclonal-antibody (170) 170
risk factors (169) 169
cardiovascular diseases - prevention & control (166) 166
proprotein convertases - metabolism (166) 166
pharmacology & pharmacy (164) 164
mice (162) 162
low density lipoproteins (156) 156
lipids (149) 149
proprotein convertase 9 - metabolism (146) 146
biochemistry & molecular biology (143) 143
subtilisin/kexin type 9 (136) 136
familial hypercholesterolemia (134) 134
heterozygous familial hypercholesterolemia (134) 134
density-lipoprotein cholesterol (133) 133
aged (132) 132
serine endopeptidases - metabolism (132) 132
proprotein convertases (128) 128
cardiovascular disease (125) 125
hypercholesterolemia - blood (121) 121
anticholesteremic agents - adverse effects (115) 115
ldl cholesterol (115) 115
serine endopeptidases (115) 115
biomarkers - blood (113) 113
efficacy (112) 112
abridged index medicus (109) 109
safety (109) 109
atherosclerosis (107) 107
monoclonal antibodies (103) 103
dyslipidemias - drug therapy (102) 102
endocrinology & metabolism (102) 102
double-blind (101) 101
evolocumab (99) 99
lipoproteins (97) 97
hyperlipoproteinemia type ii - drug therapy (96) 96
alirocumab (95) 95
statin therapy (94) 94
antibodies, monoclonal - adverse effects (93) 93
cardiovascular diseases (93) 93
adult (92) 92
proprotein convertases - genetics (92) 92
anticholesteremic agents - pharmacology (89) 89
coronary-heart-disease (89) 89
furin (89) 89
serine proteinase inhibitors - therapeutic use (89) 89
research (87) 87
analysis (85) 85
antibodies, monoclonal - pharmacology (85) 85
medicine, general & internal (84) 84
serine endopeptidases - genetics (84) 84
hypolipidemic agents - therapeutic use (82) 82
low density lipoprotein (82) 82
peripheral vascular disease (81) 81
proteins (79) 79
reducing lipids (78) 78
drug therapy, combination (76) 76
risk (75) 75
subtilisin (72) 72
cell biology (71) 71
ezetimibe (70) 70
kexin (70) 70
clinical trials (68) 68
receptors, ldl - metabolism (68) 68
anticholesteremic agents - administration & dosage (67) 67
ldl-c (67) 67
antibodies, monoclonal - administration & dosage (66) 66
clinical trials as topic (66) 66
ezetimibe - therapeutic use (66) 66
cardiovascular (65) 65
expression (65) 65
mutation (65) 65
pcsk9 inhibitors (64) 64
health aspects (63) 63
serine proteinase inhibitors - adverse effects (63) 63
proprotein convertase subtilisin/kexin type 9 (62) 62
care and treatment (61) 61
placebo-controlled trial (61) 61
cholesterol, ldl - metabolism (59) 59
activation (58) 58
drug therapy (58) 58
double-blind method (57) 57
dyslipidemias - blood (57) 57
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1038) 1038
German (29) 29
Spanish (14) 14
Czech (8) 8
Japanese (7) 7
French (6) 6
Italian (4) 4
Hungarian (3) 3
Norwegian (2) 2
Swedish (2) 2
Danish (1) 1
Dutch (1) 1
Polish (1) 1
Portuguese (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 10/2015, Volume 132, Issue 17, pp. 1648 - 1666
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the regulation of cholesterol homeostasis... 
Antibodies, monoclonal | Clinical trial | PCSK9 protein, human | antibodies, monoclonal | clinical trial | CARDIAC & CARDIOVASCULAR SYSTEMS | LOWERING THERAPY | MONOCLONAL-ANTIBODY | DENSITY-LIPOPROTEIN-CHOLESTEROL | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | STATIN-INTOLERANT PATIENTS | HEALTHY-VOLUNTEERS | CORONARY-HEART-DISEASE | PLASMA LDL CHOLESTEROL | PCSK9 GENE | Proprotein Convertases - antagonists & inhibitors | Cardiovascular Diseases - prevention & control | Humans | Serine Endopeptidases - physiology | Antibodies, Monoclonal - therapeutic use | Intestines - metabolism | Structure-Activity Relationship | Cardiovascular Diseases - enzymology | Molecular Targeted Therapy | Cardiovascular Diseases - genetics | Proprotein Convertases - genetics | Incidence | Brain - metabolism | RNA Interference | Oligonucleotides, Antisense - therapeutic use | Serine Endopeptidases - genetics | Cardiovascular Diseases - epidemiology | Protein Structure, Tertiary | Genetic Predisposition to Disease | Antibodies, Monoclonal, Humanized - therapeutic use | Serine Endopeptidases - deficiency | Liver - metabolism | Receptors, LDL - metabolism | Serine Endopeptidases - chemistry | Clinical Trials as Topic | Proprotein Convertases - chemistry | Proprotein Convertases - deficiency | Proprotein Convertases - physiology | Animals | RNA, Small Interfering - therapeutic use | Adipocytes - metabolism | Cholesterol, LDL - metabolism | Hyperlipoproteinemias - genetics | Mice | Peptide Fragments - therapeutic use | Mutation | Proprotein Convertase 9 | Monoclonal antibodies | Clinical trials | Usage | Care and treatment | Dosage and administration | Cardiovascular diseases
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9858, pp. 2007 - 2017
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2013, Volume 62, Issue 16, pp. 1401 - 1408
.... Gain-of-function mutations of the proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with hypercholesterolemia and increased risk of cardiovascular events... 
Cardiovascular | Internal Medicine | atherosclerosis | proprotein convertase subtilisin/kexin type 9 | PCSK9 | LDL cholesterol | LDL receptor | atherosclerosis LDL cholesterol LDL receptor PCSK9 proprotein convertase subtilisin/kexin type 9 | NONHUMAN-PRIMATES | LDL-CHOLESTEROL | CARDIAC & CARDIOVASCULAR SYSTEMS | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | DENSITY-LIPOPROTEIN-CHOLESTEROL | SECRETED PCSK9 | RECEPTOR-MEDIATED ENDOCYTOSIS | STATIN THERAPY | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | SERINE-PROTEASE | Proprotein Convertases - antagonists & inhibitors | Dyslipidemias - complications | Humans | Lipoproteins, LDL - genetics | Proprotein Convertases - genetics | Molecular Targeted Therapy - trends | Serine Endopeptidases - genetics | Lipid Metabolism - genetics | Lipoproteins, LDL - metabolism | Molecular Targeted Therapy - methods | Receptors, LDL - genetics | Dyslipidemias - drug therapy | Atherosclerosis - drug therapy | Proprotein Convertases - metabolism | Risk Factors | Receptors, LDL - metabolism | Atherosclerosis - complications | Hypolipidemic Agents - pharmacology | Forecasting | Atherosclerosis - metabolism | Lipid Metabolism - drug effects | Dyslipidemias - metabolism | Serine Endopeptidases - metabolism | Mutation | Proprotein Convertase 9 | Hypertension | Hypercholesterolemia | Low density lipoproteins | Mortality | Atherosclerosis | Drug therapy | Statins | Cholesterol | Protein binding | Studies | Rodents
Journal Article
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 2016, Volume 36, Issue 8, pp. 1647 - 1650
Journal Article
The Journal of biological chemistry, ISSN 1083-351X, 2016, Volume 291, Issue 7, pp. 3508 - 3519
...-). SOCS3 is also implicated in hypertriglyceridemia associated to insulin resistance. Proprotein convertase subtilisin kexin type 9 (PCSK9... 
PLASMA PCSK9 | tumor necrosis factor (TNF) | ACTIVATION | hepatocyte | proprotein convertase subtilisin | PROTEIN | insulin | CHOLESTEROL | BIOCHEMISTRY & MOLECULAR BIOLOGY | NECROSIS-FACTOR-ALPHA | APOLIPOPROTEIN-B | HUMAN ENDOTHELIAL-CELLS | INSULIN-RESISTANCE | stat-3 | HepG2 | kexin type 9 (PCSK9) | SMOOTH-MUSCLE-CELLS | MUTATIONS | suppressor of cytokine signaling 3 (SOCS3) | Proprotein Convertases - antagonists & inhibitors | Tumor Necrosis Factor-alpha - metabolism | Phosphorylation | Humans | STAT3 Transcription Factor - agonists | Tumor Necrosis Factor-alpha - genetics | Male | Janus Kinases - metabolism | Hepatocytes - metabolism | Proprotein Convertases - genetics | Recombinant Fusion Proteins - metabolism | RNA Interference | Serine Endopeptidases - genetics | Lipogenesis | STAT3 Transcription Factor - genetics | STAT3 Transcription Factor - metabolism | Recombinant Proteins - metabolism | Janus Kinases - chemistry | Signal Transduction | Mice, Inbred C57BL | Proprotein Convertases - metabolism | Insulin Resistance | Enzyme Induction | Suppressor of Cytokine Signaling Proteins - genetics | Serine Endopeptidases - chemistry | Proprotein Convertases - chemistry | Hep G2 Cells | Obesity - metabolism | Suppressor of Cytokine Signaling 3 Protein | Animals | Suppressor of Cytokine Signaling Proteins - antagonists & inhibitors | Suppressor of Cytokine Signaling Proteins - agonists | Obesity - enzymology | Protein Processing, Post-Translational | Serine Endopeptidases - metabolism | Mutation | Suppressor of Cytokine Signaling Proteins - metabolism | STAT3 Transcription Factor - antagonists & inhibitors | Hepatocytes - enzymology | Proprotein Convertase 9 | Cell Biology
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2012, Volume 59, Issue 25, pp. 2344 - 2353
...). Background Serum proprotein convertase subtilisin kexin 9 (PCSK9) binds to low-density lipoprotein receptors, increasing serum LDL-C... 
Cardiovascular | Internal Medicine | statin | low-density lipoprotein cholesterol | safety | apolipoprotein-B | PCSK9 | SAR236553/REGN727 | hypercholesterolemia | CUTANEOUS VASCULITIS | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | CHOLESTEROL | CARDIOVASCULAR OUTCOMES | LOW-DENSITY-LIPOPROTEIN | PREVENTION | REDUCTION | DISEASE | 14 RANDOMIZED-TRIALS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Proprotein Convertases - antagonists & inhibitors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Time Factors | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - blood | Double-Blind Method | Proprotein Convertases - metabolism | Treatment Outcome | Anticholesteremic Agents - adverse effects | Drug Synergism | Atorvastatin Calcium | Anticholesteremic Agents - therapeutic use | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Aged | Serine Endopeptidases - metabolism | Proprotein Convertase 9 | Care and treatment | Serine | Low density lipoproteins | Antibodies | Thrombin | Lipoprotein A | Cholesterol | Cardiovascular agents | Antilipemic agents | Viral antibodies | Complications and side effects | Hypercholesterolemia | Proteases | Monoclonal antibodies | Universities and colleges | Laboratories | Lipids | Triglycerides | Lipoproteins | Pain | Influenza | Patient safety | Population | Mutation | Clinical medicine | Diabetes | Statins
Journal Article
Angewandte Chemie (International ed.), ISSN 1433-7851, 2017, Volume 56, Issue 51, pp. 16218 - 16222
Journal Article
Cardiovascular Research, ISSN 0008-6363, 10/2016, Volume 112, Issue 1, pp. 429 - 442
Journal Article
European heart journal, ISSN 1522-9645, 2017, Volume 38, Issue 32, pp. 2499 - 2507
Journal Article